5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
July 2022
in “
Cancer Epidemiology, Biomarkers & Prevention
”
Studysummary This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on aacrjournals.org →